Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesBone Marrow or Stem Cell Services/ProceduresCPT cpt-38227-car-t-cell-ex-vivo-modification-cryopreserved-lymphocytes
    Ask Trek AI about this page

    CPT 38227: Cryopreserved T Lymphocyte Genetic Modification

    CPT code 38227 describes receipt of cryopreserved T lymphocytes (white blood cells) by a laboratory and the genetic modification of those cells for later administration as part of CAR–T therapy; this is a cellular therapy laboratory processing service typically performed in an advanced cellular therapy or specialized laboratory setting and is billed when modification occurs separate from the patient administration encounter.

    For related coverage guidance, see recent payer policy updates: Bendamustine Products Coverage Criteria, T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and Romidepsin, Brentuximab Vedotin (Adcetris®) Coverage Criteria.

    Customize your policy alerts

    Sign up for cpt 38227 policy alerts

    Get alerted when payer policies referencing 38227 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 6

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A typical patient is an adult with relapsed or refractory B-cell malignancy (for example diffuse large B-cell lymphoma) who previously underwent leukapheresis to collect autologous T lymphocytes. The patient’s cryopreserved T cells are shipped to a specialized laboratory that performs ex vivo genetic modification and expansion to produce chimeric antigen receptor T cells (CAR–T). The laboratory receives the cryopreserved specimen, performs cell thawing, transduction with a viral vector (commonly lentiviral or retroviral), cell culture and expansion, quality control testing (including sterility, viability, transduction efficiency, and release criteria), and cryopreservation of the final drug product for return to the treating facility. The treating facility then administers lymphodepleting chemotherapy, schedules infusion of the modified cells, and monitors for acute toxicities such as cytokine release syndrome and neurotoxicity. Typical site of service for the laboratory processing is an accredited cellular therapy or GMP-compliant cell processing laboratory; the clinical administration occurs in an inpatient or outpatient infusion center experienced in CAR–T therapy.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    38205Bone marrow harvest for transplantation; allogeneic or autologousPreceding collection procedure when bone marrow is used as the cell source instead of peripheral blood leukapheresis.
    38206Peripheral blood stem cell collection by apheresis for transplantation; for transplantationOften performed prior to cell processing when leukapheresis is used to collect T lymphocytes for CAR–T manufacturing.
    0537TCollection of peripheral blood mononuclear cells for CAR-T therapy; cryopreservation and shippingRelated collection and cryopreservation step performed before the laboratory receives the cryopreserved T lymphocytes for modification.
    0538TProcessing of collected autologous peripheral blood mononuclear cells for CAR-T; initial manufacturing stepsRepresents other procedural manufacturing steps that may be billed for cell processing activities; complements 38227 when different billing constructs are used.
    0540TLymphodepleting chemotherapy administration (example code for complex chemotherapy administration)Chemotherapy administered at the treating facility prior to infusion of the modified product; part of the overall clinical workflow.
    96413Chemotherapy administration, intravenous infusion technique; up to 1 hourCommonly used for lymphodepleting regimens given prior to CAR–T infusion and billed by the treating facility.

    Related Modifiers

    8 rows

    ModifierDescriptionWhen to Use
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    23Modifier -23 (Unusual Anesthesia) is used on anesthesia service CPT codes when a procedure that normally requires no anesthesia or only local anesthesia must be performed under general anesthesia…- Use modifier -23 only on anesthesia CPT codes (00100–01999) when a procedure that normally requires no anesthesia or only local anesthesia must be performed under general anesthesia because of…
    50Modifier –50 (Bilateral Procedure) is appended to a CPT code when an identical procedure is performed on paired anatomical structures during the same operative session. The AMA states to add…- Use modifier -50 when the same CPT surgical, diagnostic, or radiology procedure is performed on paired anatomical structures (both sides of the body) during the same operative/session by the same…
    51Modifier –51 (Multiple Procedures) is used when the same provider performs multiple procedures in the same session to identify secondary, non‑exempt procedures and indicate payment reduction logic…- Use modifier -51 when the same provider performs multiple distinct procedures during the same patient encounter: report the highest‑valued procedure first (no modifier) and append -51 to…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    2080P0208X
    207RH0000X
    2083P0901X
    363L00000X
    208D00000X
    385H00000X
    101YP2500X
    246ZN0300X

    Related Payer Policy Updates

    Specialty: Hematology/Oncology1 / 3

    10 rows

    PolicyPayerEffective Date
    Bendamustine Products Coverage Criteriablue cross blue shield - tennessee2027-01-30
    T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and RomidepsinMass General Brigham Health Plan2027-01-04
    Brentuximab Vedotin (Adcetris®) Coverage Criteriablue cross blue shield - tennessee2026-12-31
    Pemetrexed Coverageblue cross blue shield - tennessee2026-12-31
    Tumor Treatment Fields - Medical PolicyHealth-New-England2026-12-01
    Extracorporeal PhotopheresisCigna2026-11-15
    VonvendiCigna2026-11-15
    Hematology - AphexdaCigna2026-11-15
    Extracorporeal PhotopheresisCigna2026-11-15
    Yartemlea (narsoplimab-wuug) Coverage for TA-TMANeighborhood Health Plan of Rhode Island2026-11-01

    Related Codes

    CPT-38204-DONOR-SEARCH-HPC-ACQUISITION-MANAGEMENT

    CPT 38204: Donor Search and Hematopoietic Progenitor Cell Acquisition

    CPT-38205-APHERESIS-HPC-PERIPHERAL-BLOOD-HARVEST

    CPT 38205: Apheresis Hematopoietic Progenitor Cell Harvest

    CPT-38206-AUTOLOGOUS-HPC-APHERESIS-COLLECTION

    CPT 38206: Autologous Hematopoietic Progenitor Cell Apheresis

    CPT-38207-HEMATOPOIETIC-PROGENITOR-CELL-PRESERVATION-STORAGE

    CPT 38207: Management of Hematopoietic Progenitor Cell Preservation

    CPT-38208-THAW-PREPARATION-HEMATOPOIETIC-PROGENITOR-CELLS

    CPT 38208: Thawing of Previously Frozen Hematopoietic Progenitor Cells

    CPT-38209-HPC-THAWING-AND-WASHING-FOR-TRANSPLANTATION

    CPT 38209: Thaw and Wash Hematopoietic Progenitor Cells for Transplant

    CPT-38210-T-CELL-DEPLETED-HEMATOPOIETIC-PROGENITOR-CELL-PREPARATION

    CPT 38210: T-Cell–Reduced Hematopoietic Progenitor Cell Preparation

    CPT-38211-HEMATOPOIETIC-PROGENITOR-CELL-TUMOR-REDUCTION-PROCESSING

    CPT 38211: Hematopoietic Progenitor Cell Enrichment and Tumor Depletion

    CPT-38212-HPC-RED-CELL-DEPLETION-PREPARATION

    CPT 38212: HPC Red Cell Depletion for Transplant Preparation

    CPT-38213-HPC-SOLUTION-PREPARATION-PLATELET-REDUCTION

    CPT 38213: Hematopoietic Progenitor Cell Preparation to Reduce Platelets

    Showing 1–10 of 20

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.